Figure 1.

Changes in parenteral nutrition. Considering all patients, reduction of intravenous calories was significant after 12, 24 and 48 weeks and beyond 12 months of teduglutide treatment. Reduction of total intravenous fluid support was significant after 24 and 48 weeks as well as after treatment of over 12 months (a). The proportion of patients that reduced intravenous fluids by 20% or more was 33.3% after 24 weeks, 54.5% after 48 weeks and 71.3% in treatment of over 12 months. For intravenous calories the proportion was 36.4%, 70% and 85.7% after 24, 48 and over 12 months, respectively (b). The average number of days of parenteral support per week decreased from 5.6 days at baseline to 4.2 days after 48 weeks of treatment and to 2.0 days beyond 12 months of treatment. The latter showed statistical significance (c) (*p < 0.05). Mo, months; PN, parenteral nutrition; W, weeks.